Dexcom Inc
XMUN:DC4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dexcom Inc
XMUN:DC4
|
US |
|
Pangenomic Health Inc
F:LL3
|
CA |
|
A
|
Air Products and Chemicals Inc
F:AP3
|
US |
|
A
|
American Diversified Holdings Corp
OTC:ADHC
|
US |
|
E
|
eBay Inc
F:EBA
|
US |
|
N
|
Newpath Resources Inc
OTC:RDYFF
|
CA |
|
C
|
Caterpillar Inc
DUS:CAT1
|
US |
|
I Grandi Viaggi SpA
F:95H
|
IT |
|
A
|
Alpha Divisions PCL
SET:ALPHAX
|
TH |
|
Philogen SpA
F:78Q
|
IT |
|
L
|
L'Oreal SA
DUS:LORA
|
FR |
|
H
|
Halliburton Co
XHAM:HAL
|
US |
|
Preveceutical Medical Inc
OTC:PRVCF
|
CA |
|
F
|
Futebol Clube do Porto Futebol Sad
XMUN:FBC
|
PT |
|
A
|
Alucon PCL
SET:ALUCON
|
TH |
|
Mineral Road Discovery Inc
F:7C9
|
CA |
Earnings Calls
Last Earnings Call
Revenue: Dexcom reported second-quarter revenue of $1.31 billion, up 13% year over year on a reported basis and 12% organically, with growth led by strong U.S. and international demand.
Guidance: Management raised full-year revenue guidance to $5.18 billion to $5.25 billion and also lifted gross margin, operating margin, and EBITDA margin targets.
Demand: New customer starts stayed at a record level globally, with a sequential uptick in the U.S. and broad-based strength across patient groups.
Coverage: The company said its CONNECT trial strengthens the case for broader reimbursement in non-insulin type 2 diabetes and that it has already submitted the data to CMS.
Products: Dexcom highlighted the launch of the redesigned Stelo app, progress on Smart Basal, the rollout of G7 15 Day, and Health Canada’s clearance of G7 15 Day.
Cash Return: Dexcom generated over $600 million of free cash flow in the first half and repurchased about $600 million of stock in Q2 under its $1 billion buyback plan.